A phase II trial was performed to evaluate the efficacy and @entity137 of the novel combination of @entity1206 and @entity1311 as first-line chemotherapy in @entity1 with stages IIIB and @entity1149 . From January 1997 to September 1999, 34 @entity1 (9 stage IIIB and 25 stage IV) received a regimen consisting of the following: @entity1206 30 mg/m2 20 minutes intravenous (i.v.) infusion, days 1 and 8; and @entity1311 135 mg/m2 3-hour i.v. (starting 1 hour after @entity1206 ) on day 1. Cycles were repeated every 28 days until progression of disease or unacceptable @entity137 development. The median age was 57 years (range 41-70 years); median performance status was 1. Histology was as follows: squamous cell in 24 (71%), large cell in 1 (3%), and @entity420 in 9 (26%). All @entity1 are evaluable for @entity137 , whereas 30 are evaluable for response (4 @entity1 refused treatment). Objective response was recorded in 4 of 30 @entity1 (13%, 95% CI 1-25%). No complete response was observed. Partial response was recorded in 4 @entity1 (13%), no change in 10 @entity1 (34%), and progressive disease in 16 @entity1 (53%). The median time to treatment failure was 4 months and median survival was 9 months. The limiting @entity137 was myelosuppression: @entity1431 in 23 @entity1 (68%), whereas @entity1398 was observed in 25 @entity1 (78%). @entity1897 developed in 14 @entity1 (41%) (without G3 or G4 episodes), and @entity1142 (G1-G2: 10 @entity1 ), @entity925 (G1-G2: 11 @entity1 ), @entity294 (G1-G2: 7 @entity1 ), and @entity3136 were observed in 7 @entity1 . @entity1206 - @entity1311 combination showed only modest activity against locoregionally advanced or metastatic NSCLC.

XXXX and @entity1311 for locoregional advanced or metastatic @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['IV non-small-cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine', 'Vinorelbine'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['Peripheral neurotoxicity'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity1206 :: (MESH:C030852,Chemical) :: ['Vinorelbine']
